Physician Wealth Advisors Inc. Acquires 509 Shares of Pfizer Inc. (NYSE:PFE)

Physician Wealth Advisors Inc. lifted its position in Pfizer Inc. (NYSE:PFEFree Report) by 5.1% in the 4th quarter, Holdings Channel reports. The fund owned 10,571 shares of the biopharmaceutical company’s stock after acquiring an additional 509 shares during the quarter. Physician Wealth Advisors Inc.’s holdings in Pfizer were worth $299,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PFE. Fulton Bank N.A. increased its position in Pfizer by 4.7% during the 3rd quarter. Fulton Bank N.A. now owns 176,239 shares of the biopharmaceutical company’s stock valued at $5,846,000 after buying an additional 7,991 shares in the last quarter. Portside Wealth Group LLC purchased a new stake in Pfizer during the 2nd quarter valued at $2,072,000. Adage Capital Partners GP L.L.C. boosted its stake in Pfizer by 40.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares during the last quarter. Brookstone Capital Management boosted its stake in Pfizer by 88.5% during the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after purchasing an additional 212,369 shares during the last quarter. Finally, ETF Store Inc. boosted its stake in Pfizer by 12.0% during the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 727 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Barclays cut their target price on Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. UBS Group dropped their price target on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research note on Thursday, December 14th. Finally, Truist Financial dropped their price target on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $36.88.

View Our Latest Report on Pfizer

Pfizer Price Performance

NYSE:PFE traded down $0.17 on Tuesday, reaching $27.55. 30,662,538 shares of the company’s stock traded hands, compared to its average volume of 43,380,047. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a 50-day simple moving average of $27.43 and a 200-day simple moving average of $29.29. The firm has a market cap of $156.00 billion, a PE ratio of 76.53, a P/E/G ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $42.22.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the firm earned $1.14 earnings per share. The business’s quarterly revenue was down 41.3% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.